EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Psychemedics Corporation (PMDI) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Psychemedics Corporation $1.82, price $2.49, upside -26.9%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US

PC Psychemedics Corporation logo Thin data Sep 24, 2026

Psychemedics Corporation

PMDI · US

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value $1.82 · Overvalued (−27%)
!Quality 55/100
!Weak Growth (revenue 3y −7.5 %/yr)
!Loss-making · -9.5% net margin (TTM)
✓Low debt · generates free cash flow
!Trails peers (4/11)
!Narrow moat 15/100
!Evidence only low, so the estimate is less certain
Watch Psychemedics Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$8.25 $1.38 Fair Value $1.82 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $1.38 – $8.25 · fair‑value band $1.40 – $2.27 · the $2.49 price screens above the $1.82 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Psychemedics in your weekly email

Every Wednesday you see whether Psychemedics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally.

Show more

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. The company provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising aka K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Dallas, Texas.

Stock analysis

Psychemedics Corporation (PMDI) currently trades at $2.49, while our model-based Fair Value estimate is $1.82, implying the stock looks roughly 36.8% overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $1.95 per share, and 0 of the 11 models we run sit above the $2.49 price.

Bear case: the Asset-Based group reads lowest at $0.5600, and 11 of the 11 models stay below the price. Evidence for this calculation is low.

Scenario range: $1.40 (bear) to $2.27 (bull), the price of $2.49 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Psychemedics Corporation reported revenue of $19.7M in FY2024 versus $21.4M in FY2020, a compound −2.0%/yr. Reported net income was −$1.9M in FY2024.

Key figures

Market cap $15.2M · P/S ratio 0.77 · EPS (TTM) $−0.3200 · Net margin −9.5% · Return on equity −31.5% · Return on assets (EBIT) −15.3% · Operating margin 3.8% · Revenue (TTM) $19.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 80% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −27%, PMDI screens richer than that median.

Fair Value models

Bear $1.40 Fair Value $1.82 Bull $2.27
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $1.46 $1.93 $2.76 78
Growth DCF $1.51 $1.96 $2.71 76
Owner Earnings $0.3800 $0.4600 $0.5900 75
All 11 models by family
DCF Models
FCF DCF $1.46 $1.93 $2.76 78
Owner Earnings $0.3800 $0.4600 $0.5900 75
5Y Revenue Exit $1.38 $1.92 $2.71 70
5Y EBITDA Exit $0.8600 $1.01 $1.22 74
10Y Revenue Exit $1.37 $1.77 $2.20 65
10Y EBITDA Exit $1.09 $1.22 $1.34 67
Multiples
EV/EBITDA $0.5100 $0.6100 $0.7200 67
EV/Revenue $1.44 $1.97 $2.51 54
Asset-Based
NCAV (Graham) $0.4200 $0.5600 $0.8400 54
Growth DCF
Growth DCF $1.51 $1.96 $2.71 76
Rev-Margin DCF $1.38 $1.95 $2.65 70

Open the full fair value analysis →

Notify me when PMDI reaches fair value

Put PMDI on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 55/100

Of which business quality 57 · Market factors (momentum, volatility) 68

Profitability 40
Margins and returns on capital today
Quality Growth 58
Are margins and returns improving?
Cashflow 51
Earnings quality: real cash, not paper profit
Fin. Strength 69
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 52
Calm price path (market factor)
Momentum 73
Price trend over the last 3–12 months (market factor)
52W Momentum 76
Distance to the 52-week high (market factor)
Net Issuance 40
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 10/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−10.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−28.4% (2020) → −9.6% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+4.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +2.4% a year for the price.

PMDI screens 37% overvalued. Compare with Thermo Fisher Scientific Inc →

Compare Psychemedics Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 55 · Above median
Fair Value upside −27% · Above median
Profitability
Return on assets −11% · Bottom 25%
Net margin (TTM) −9% · Below median
Operating margin (TTM) 4% · Below median
Growth and dividend
Revenue growth −12% · Bottom 25%
Balance sheet
Debt / equity 0.06× · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 2.97× · Pricier than median
P/S (TTM) 0.77× · Cheaper than median
P/FCF 18.1× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 8
HEALTH (low debt)97 · sector 95
DIVIDEND (yield)0 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $665.30 $682.58 +3%
Danaher Corporation DHR $221.09 $207.76 −6%
WuXi AppTec Co 2359 HK$207.60 HK$228.36 +10%
Lonza Group LONN CHF 570.00 CHF 151.69 −73%
IDEXX Laboratories, Inc IDXX $522.02 $495.84 −5%
Agilent Technologies, Inc A $165.32 $63.90 −61%
Waters Corporation WAT $425.74 $106.31 −75%
IQVIA Holdings IQV $270.09 $295.80 +10%
Illumina, Inc ILMN $255.38 $280.92 +10%
Mettler-Toledo International Inc MTD $1,491 $635.75 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Psychemedics Corporation · Fair Value
$1.82 −37%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Psychemedics Corporation Fair Value". https://www.fairvalue-calculator.com/stock/PMDI

Frequently asked questions

Is Psychemedics Corporation (PMDI) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $1.82 versus a price of $2.49, about −27% upside (overvalued).
What is the fair value of PMDI?
Our model-based fair value for Psychemedics Corporation is $1.82 (as of Sep 24, 2026), built from audited fundamentals. The current price: $2.49.
What is the quality score of PMDI?
Psychemedics Corporation has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Psychemedics Corporation (PMDI)?
Our model-based price target is the fair value of $1.82 (as of Sep 24, 2026) from 11 valuation models. Cautious scenario $1.40, optimistic scenario $2.27. It is a calculation from audited fundamentals, not an analyst target.
What is the Psychemedics Corporation stock forecast for 2026?
Our models put fair value at $1.82, about −27% upside versus a price of $2.49 (overvalued). Cautious scenario $1.40, optimistic scenario $2.27. The calculation is refreshed regularly with new filings.
What is the revenue of Psychemedics Corporation (PMDI)?
Psychemedics Corporation reported trailing-twelve-month revenue of about $19.7M (latest available figure, as of Sep 24, 2026).
What growth is priced into Psychemedics Corporation (PMDI)?
For today's price to be fair in a discounted-cash-flow model, Psychemedics Corporation would have to grow free cash flow by +4.8 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew -2.0 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of PMDI use?
Our models discount Psychemedics Corporation at 9.0 %: a base by market capitalisation (nano), damped by beta 0.71, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Psychemedics Corporation that is +4.8 % per year a year over ten years, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has Psychemedics Corporation (PMDI) delivered so far?
Over the past 4 years revenue at Psychemedics Corporation grew -2.0 % a year. The price currently implies +4.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Psychemedics Corporation (PMDI) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Psychemedics Corporation (+4.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Psychemedics Corporation (PMDI)?
The free-cash-flow yield on the price is 5.53 %: that much free cash flow Psychemedics Corporation produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Psychemedics Corporation (PMDI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Psychemedics Corporation it is $1.82 per share (as of Sep 24, 2026), against a price of $2.49. It is the blended result of 11 valuation models (cash flow, earnings, asset, dividend).
Is Psychemedics Corporation stock overvalued or undervalued in 2026?
As of Sep 24, 2026, PMDI trades above its calculated fair value: price $2.49, fair value $1.82, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PMDI?
No. The price is what the market pays today ($2.49); the fair value is what the company's own numbers justify ($1.82). For Psychemedics Corporation the two are $0.6700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Psychemedics Corporation worth?
The market values Psychemedics Corporation at about $15.2M (market capitalisation, as of Sep 24, 2026). Per share that is $2.49; our models calculate a fair value of $1.82 per share.
What do the bullish and bearish scenarios say about PMDI?
Our models span a range for Psychemedics Corporation: cautious scenario $1.40, base $1.82, optimistic $2.27 per share (as of Sep 24, 2026, price $2.49). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Psychemedics Corporation (PMDI)?
Balance-sheet figures for Psychemedics Corporation (as of Sep 24, 2026): return on equity −31.5%, debt of 0.06 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is PMDI from its 52-week high?
Psychemedics Corporation trades at $2.49, at its 52-week high of $2.50 and 80% above the low of $1.38 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $1.82 is for.
Which stocks are comparable to Psychemedics Corporation?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Psychemedics Corporation stock attractive at the current price?
The data as of Sep 24, 2026: price $2.49, calculated fair value $1.82 (−27%), Quality Score 55/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PMDI calculated?
We run Psychemedics Corporation through 11 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.82, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Psychemedics Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Psychemedics Corporation (PMDI)?
The closing price on Sep 23, 2026 was $2.49. Our model-based fair value is $1.82, about −27% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Psychemedics Corporation right now?
The price sits above even our optimistic bull case ($2.27). The favourable scenario is already priced in. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Psychemedics Corporation

How large is the market capitalisation of Psychemedics Corporation (PMDI)?
The market capitalisation of Psychemedics Corporation is $15.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Psychemedics Corporation (PMDI)?
The price-to-sales ratio of Psychemedics Corporation is 0.77 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Psychemedics Corporation (PMDI)?
Earnings per share at Psychemedics Corporation are $−0.3200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Psychemedics Corporation (PMDI)?
The net margin of Psychemedics Corporation is −9.5% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Psychemedics Corporation (PMDI)?
The return on equity (ROE) of Psychemedics Corporation is −31.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Psychemedics Corporation (PMDI)?
On an EBIT basis the return on assets of Psychemedics Corporation is −15.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Psychemedics Corporation (PMDI)?
The operating margin of Psychemedics Corporation is 3.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Psychemedics Corporation (PMDI)?
Revenue at Psychemedics Corporation is growing −11.5% versus a year earlier (3y avg −7.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
Free · no account needed

Watch Psychemedics Corporation in the live analysis

One click puts Psychemedics Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.